keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer, breast cancer, thromboembolism

keyword
https://www.readbyqxmd.com/read/30077526/patients-with-cancer-and-atrial-fibrillation-treated-with-doacs-a-prospective-cohort-study
#1
Maria Cristina Vedovati, Michela Giustozzi, Paolo Verdecchia, Lucia Pierpaoli, Serenella Conti, Melina Verso, Francesco Di Filippo, Emanuela Marchesini, Giulio Bogliari, Giancarlo Agnelli, Cecilia Becattini
BACKGROUND: Limited data are available on the use of direct oral anticoagulants (DOACs) in patients with cancer and atrial fibrillation (AF). METHODS: Consecutive patients with non-valvular AF treated with DOACs were enrolled in a prospective cohort with the aim of evaluating thromboembolic (ischemic stroke or transient ischemic attack or systemic embolism) and major bleeding (MB) events according to presence and type of cancer. The risk of study outcomes over time was compared using Kaplan-Meier method and log-rank test or Cox proportional hazards regression...
July 29, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29980524/cancer-associated-thrombosis-in-patients-with-implanted-ports-a-prospective-multicenter-french-cohort-study-oncocip
#2
Hervé Decousus, Aurélie Bourmaud, Pierre Fournel, Laurent Bertoletti, Carine Labruyère, Emilie Presles, Adel Merah, Silvy Laporte, Laetitia Stefani, Francesco Del Piano, Jean-Philippe Jacquin, Guy Meyer, Franck Chauvin
The need to accurately identify cancer outpatients at high risk of thrombotic complications is still unmet. In a prospective, multicenter cohort study, consecutive adult patients with a solid tumor and implanted port underwent 12-month follow-up. Our primary objective was to identify risk factors for (1) catheter-related thrombosis, defined as ipsilateral symptomatic upper-limb deep-vein thrombosis with or without pulmonary embolism, and (2) venous thromboembolism other than catheter-related, defined as any symptomatic superficial- or deep-vein thrombosis (other than catheter-related) or pulmonary embolism, and incidental pulmonary embolism...
July 6, 2018: Blood
https://www.readbyqxmd.com/read/29848769/venous-thromboembolism-in-patients-with-cancer-design-and-rationale-of-a-multicentre-prospective-registry-cancer-vte-registry
#3
Yasuo Ohashi, Masataka Ikeda, Hideo Kunitoh, Mitsuru Sasako, Takuji Okusaka, Hirofumi Mukai, Keiichi Fujiwara, Mashio Nakamura, Tetsuya Kimura, Kei Ibusuki, Masato Sakon
INTRODUCTION: Patients with cancer are at higher risk of venous thromboembolism (VTE) than the general population as the malignancy itself and treatment modalities, including medication and surgery, contribute to the risk of developing VTE. Furthermore, patients with cancer developing VTE have a worse prognosis than those without cancer. There are no multicentre prospective data on the occurrence and treatment of VTE in patients with cancer in Japan, and data on the outcomes, complications and incidence of VTE in these patients have not been reported...
May 30, 2018: BMJ Open
https://www.readbyqxmd.com/read/29704767/management-of-cancer-associated-upper-extremity-deep-vein-thrombosis-with-and-without-venous-catheters-at-a-tertiary-care-center
#4
Said Y ALKindi, Chatree Chai-Adisaksopha, Matthew Cheah, Lori-Ann Linkins
INTRODUCTION: Data on management of upper extremity deep vein thrombosis (UEDVT) in patients with cancer is limited. The objective of this study was to determine risk factors for UEDVT and the rates of recurrence and bleeding in a real-world setting. METHODS: Retrospective review of consecutive patients assessed for cancer-associated UEDVT. Outcome measures were recurrent venous thromboembolism (VTE), and major and clinically relevant non-major bleeding (CRNMB)...
June 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29540440/risk-and-prognosis-of-cancer-after-lower-limb-arterial-thrombosis
#5
Jens Sundbøll, Katalin Veres, Erzsébet Horváth-Puhó, Kasper Adelborg, Henrik Toft Sørensen
Background -Venous thromboembolism can be a presenting symptom of cancer, but the association between lower limb arterial thrombosis and cancer is unknown. We therefore examined cancer risk and prognosis of cancer in patients with lower limb arterial thrombosis. Methods -Using nationwide population-based Danish medical registries, we identified all patients diagnosed with first-time lower limb arterial thrombosis (1994-2013) and followed them until the occurrence of any subsequent cancer diagnosis, emigration, death, or 30 November 2013, whichever came first...
March 14, 2018: Circulation
https://www.readbyqxmd.com/read/29540105/clotassist-a-program-to-treat-cancer-associated-thrombosis-in-an-outpatient-pharmacy-setting
#6
Jacob C Easaw, Susan McCall, Adrian Azim
Stable cancer patients diagnosed with a pulmonary embolus or deep vein thrombosis are commonly referred to the emergency department for management. This practice strains an already overburdened emergency department and is associated with long wait times and poor disease/injection education for patients. This pilot study sought to determine if stable cancer patients with newly diagnosed cancer-associated thrombosis could be effectively managed by community-based pharmacists who followed an evidence-based protocol to prescribe and initiate low-molecular weight heparin therapy...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29353682/predicting-the-risk-of-recurrent-venous-thromboembolism-in-patients-with-cancer-a-prospective-cohort-study
#7
Nick van Es, Martha Louzada, Marc Carrier, Vicky Tagalakis, Peter L Gross, Sudeep Shivakumar, Marc A Rodger, Philip S Wells
BACKGROUND: The risk of recurrent venous thromboembolism (VTE) in cancer patients despite anticoagulant therapy is high. Clinical factors and pro-coagulant markers may identify high-risk patients and guide decisions about intensifying anticoagulation therapy. AIMS: To evaluate whether serial measurements of pro-coagulant markers can identify patients at high risk of recurrent VTE. METHODS: In this multicenter, prospective cohort study, patients with active cancer and acute deep vein thrombosis or pulmonary embolism were enrolled...
March 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29353416/physicians-decision-about-long-term-thromboprophylaxis-in-cancer-outpatients-cat-axis-a-case-vignette-study-on-clinical-practice-in-france
#8
Florian Scotté, I Elalamy, D Mayeur, G Meyer
PURPOSE: Data on long-term venous thromboembolism prophylaxis in cancer outpatients remain scarce. In the absence of clear and consistent treatment guidelines, our objectives were to describe and better understand clinical practice and to identify factors influencing the use of thromboprophylaxis. METHODS: CAT AXIS was a multicentred cross-sectional study based on the completion of physician-profile questionnaires and the assessment of 10 e-mailed credible clinical scenarios of lung, colon and breast cancers by each of participants using the case vignette-validated method...
June 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28868021/a-case-of-recurrent-breast-cancer-identified-by-pulmonary-tumor-thrombotic-microangiopathy
#9
Tomomi Abe, Ippei Fukada, Taro Shiga, Hidetomo Morizono, Koichi Ikebata, Tomoko Shibayama, Kokoro Kobayashi, Takuji Iwase, Shinji Ohno, Yoshinori Ito
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, cancer-related, pulmonary complication that causes hypoxia and pulmonary hypertension. We report on a 42-year-old woman who was diagnosed with recurrent breast cancer that was detected due to the presence of PTTM. Eleven months after surgery for heterochronous bilateral cancer of the left breast, she developed progressive dyspnea but computerized tomography showed no pulmonary thromboembolism, and a transthoracic echocardiography revealed mild pulmonary hypertension...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28818202/risk-of-arterial-thromboembolism-in-patients-with-cancer
#10
MULTICENTER STUDY
Babak B Navi, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin, Mitchell S V Elkind, Katherine S Panageas, Lisa M DeAngelis
BACKGROUND: The risk of arterial thromboembolism in patients with cancer is incompletely understood. OBJECTIVES: The authors aimed to better define this epidemiological relationship, including the effects of cancer stage. METHODS: Using the Surveillance Epidemiology and End Results-Medicare linked database, the authors identified patients with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011...
August 22, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28807983/cancer-associated-pathways-and-biomarkers-of-venous-thrombosis
#11
REVIEW
Yohei Hisada, Nigel Mackman
Cancer patients have an increased risk of venous thromboembolism (VTE). In this review, we summarize common and cancer type-specific pathways of VTE in cancer patients. Increased levels of leukocytes, platelets, and tissue factor-positive (TF+ ) microvesicles (MVs) are all potential factors that alone or in combination increase cancer-associated thrombosis. Patients with lung or colorectal cancer often exhibit leukocytosis. Neutrophils could increase VTE in cancer patients by releasing neutrophil extracellular traps whereas monocytes may express TF...
September 28, 2017: Blood
https://www.readbyqxmd.com/read/28681634/sex-differences-in-patients-with-occult-cancer-after-venous-thromboembolism
#12
Luis Jara-Palomares, Remedios Otero, David Jiménez, Juan Manuel Praena-Fernández, Agustina Rivas, Carme Font, Philip S Wells, Raquel López-Reyes, José González-Martínez, Manuel Monreal
In patients with venous thromboembolism (VTE), male sex has been associated with an increased risk of occult cancer. The influence of sex on clinical characteristics, treatment, cancer sites, and outcome has not been thoroughly investigated yet. We used the Registro Informatizado Enfermedad TromboEmbólica registry to compare the clinical characteristics, treatment strategies, cancer sites, and clinical outcomes in patients with VTE having occult cancer, according to sex. As of June 2014, 5864 patients were recruited, of whom 444 (7...
April 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28550032/a-predictive-score-for-thrombosis-associated-with-breast-colorectal-lung-or-ovarian-cancer-the-prospective-compass-cancer-associated-thrombosis-study
#13
Grigoris T Gerotziafas, Ali Taher, Hikmat Abdel-Razeq, Essam AboElnazar, Alex C Spyropoulos, Salem El Shemmari, Annette K Larsen, Ismail Elalamy
BACKGROUND: The stratification of outpatients on chemotherapy for breast, colorectal, lung, and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical need. The derivation of a risk assessment model (RAM) for VTE in these patients was the aim of the study "Prospective Comparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real life patients-Cancer Associated Thrombosis" (COMPASS-CAT). PATIENTS AND METHODS: The derivation cohort consisted of 1,023 outpatients...
October 2017: Oncologist
https://www.readbyqxmd.com/read/28441110/effects-of-the-us-food-and-drug-administration-boxed-warning-of-erythropoietin-stimulating-agents-on-utilization-and-adverse-outcome
#14
John Bian, Brian Chen, Dawn L Hershman, Norman Marks, LeAnn Norris, Richard Schulz, Charles L Bennett
Purpose In March 2007, a US Food and Drug Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse events, such as venous thromboembolism (VTE). We evaluated the US Food and Drug Administration's boxed warning of ESAs used to treat chemotherapy-induced anemia because evidence on the effectiveness of boxed warnings remains inconclusive. Patients and Methods Using 2004 to 2009 SEER-Medicare data, we exploited a natural experiment to examine the effects of ESA boxed warnings on utilization and risk of VTE...
June 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28397505/-current-recommendations-for-the-prevention-and-treatment-of-venous-thromboembolism-in-cancer-patients
#15
REVIEW
J Halámková, M Penka
About 20% of patients suffer from venous thromboembolism (VTE) during oncology disease. Active cancer, along with cancer therapy, increases the risk of VTE, especially in the first 6 months after diagnosis. Most often VTE accompanies haematological malignancies and CNS tumours, and gastrointestinal, breast, lung, ovary and uterine cancer. The presence of distant metastases, together with the implantation of a central venous catheter, increases the risk even more. A cancer patient also has a 2-5× higher risk of recurrence of VTE during anticoagulant therapy than patients without a malignancy, as well as a 2-6× higher risk of serious bleeding...
December 0: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/27884650/the-clinical-course-of-venous-thromboembolism-may-differ-according-to-cancer-site
#16
Isabelle Mahé, Jean Chidiac, Laurent Bertoletti, Carme Font, Javier Trujillo-Santos, Marisa Peris, Cristina Pérez Ductor, Santiago Nieto, Elvira Grandone, Manuel Monreal
BACKGROUND: We hypothesized that the clinical course of venous thromboembolism in patients with active cancer may differ according to the specificities of primary tumor site. AIM AND METHODS: We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer)...
March 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/27835633/tumor-specific-d-dimer-concentration-ranges-and-influencing-factors-a-cross-sectional-study
#17
Jing Yu, Dongqing Li, Dansheng Lei, Feng Yuan, Feng Pei, Huifeng Zhang, Anming Yu, Kun Wang, Hu Chen, Liang Chen, Xianglei Wu, Xianli Tong, Yefu Wang
D-dimer level in cancer patients is associated with risk of venous thromboembolism and deep venous thrombosis. Most cancer patients have "abnormal" D-dimer levels based on the current normal reference range. To investigate tumor-specific D-dimer reference range, we compared D-dimer levels for nine different tumour types with healthy controls by using simultaneous quantile regression and constructing a median, 5th percentile, and 95th percentile model of normal tumour D-dimer concentration. Associations with tumour primary site, stage, pathological type, and treatment were also explored...
2016: PloS One
https://www.readbyqxmd.com/read/27161728/po-40-real-life-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-cancer-associated-venous-thromboembolism-data-from-a-prospective-cohort
#18
A Mancuso, M C Vedovati, L Pierpaoli, U Paliani, S Conti, E Filippucci, A Ascani, S Radicchia, G Galeotti, G Agnelli, C Becattini
INTRODUCTION: Cancer associated thrombosis (CAT) has an increased risk of recurrent venous thromboembolism (VTE). Type, stage of cancer and chemotherapy (CHT) influence thromboembolic risk. The use of novel oral anticoagulants (NOACs) is controversial in patients with CAT. AIM: The aim of this study is to assess mortality, recurrent VTE and bleeding complications in patients with CAT and in patients without cancer receiving NOACs. MATERIALS AND METHODS: Consecutive patients with acute objectively confirmed VTE receiving NOACs within 1 month from diagnosis are included from September 2013 in an ongoing prospective cohort study...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27161697/po-07-excluding-pulmonary-embolism-in-cancer-patients-using-the-wells-rule-and-age-adjusted-d-dimer-testing-an-individual-patient-data-meta-analysis
#19
N van Es, T van der Hulle, J van Es, P L den Exter, R A Douma, R J Goekoop, I C M Mos, J G Garcia, P W Kamphuisen, M V Huisman, F A Klok, H R Büller, P M Bossuyt
INTRODUCTION: Among patients with clinically suspected pulmonary embolism (PE), imaging and anticoagulant treatment can be safely withheld in approximately one-third of patients based on the combination of a "PE unlikely" Wells score and a D-dimer below the age-adjusted threshold. The clinical utility of this diagnostic approach in cancer patients is less clear. AIM: To evaluate the efficiency and failure rate of the original and simplified Wells rules in combination with age-adjusted D-dimer testing in patients with active cancer...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27161683/oc-11-anticoagulation-therapy-in-selected-cancer-patients-at-risk-of-recurrence-of-venous-thromboembolism
#20
A Young, J Phillips, H Hancocks, C Hill, N Joshi, A Marshall, J Grumett, J A Dunn, A Lokare, O Chapman
INTRODUCTION: Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical problem. The overall impact of VTE on cancer patients can be considerable. Targeted patient selection by identifying patients with clinically significant recurrent VTE may have wider health economic benefits whilst reducing patient risk through over-treatment. In the UK, dalteparin is one licensed anticoagulant for the extended treatment and prevention of recurrence of VTE in cancer patients...
April 2016: Thrombosis Research
keyword
keyword
170779
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"